Literature DB >> 29731125

Utility of intravoxel incoherent motion diffusion-weighted imaging in predicting early response to concurrent chemoradiotherapy in oesophageal squamous cell carcinoma.

F P Li1, H Wang2, J Hou1, J Tang2, Q Lu1, L L Wang1, X P Yu3.   

Abstract

AIM: To investigate the utility of intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) in predicting the early response to concurrent chemoradiotherapy (CRT) in oesophageal squamous cell carcinoma (OSCC).
MATERIALS AND METHODS: Thirty-three patients with OSCC who received CRT underwent IVIM-DWI at three time points (before CRT, at the end of radiotherapy 20 Gy, and immediately after CRT). After CRT, the patients were divided into the responders (complete response or partial response) and the non-responders (stable disease) based on RECIST 1.1. The IVIM-DWI parameters (apparent diffusion coefficient [ADC], true diffusion coefficient [D], the pseudo-diffusion coefficient [D*], and the perfusion fraction [f]) values and their percentage changes (Δvalue) at different time points were compared between the responders and the non-responders. Receiver-operating characteristic (ROC) curve analysis was used to determine the efficacy of IVIM-DWI parameters in identifying the response to CRT.
RESULTS: The tumour regression ratio showed negative correlations with ADCpre (r=-0.610, p=0.000), ADC20 Gy (r=-0.518, p=0.002), Dpre (r=-0.584, p=0.000), and D20 Gy (r=-0.454, p=0.008), and positive correlation with ΔD20 Gy (r=0.361, p=0.039) and ΔDpost (r=0.626, p=0.000). Compared to the non-responders, the responders exhibited lower ADCpre, Dpre, ADC20 Gy, and D20 Gy, as well as higher ΔADC20 Gy, ΔD20 Gy, and ΔDpost (all p<0.05). Dpre had the highest sensitivity (92.9%) and value of area under the ROC curve (0.865) in differentiating the responders from the non-responders.
CONCLUSION: Diffusion-related IVIM-DWI parameters (ADC and D) are potentially helpful in predicting the early treatment effect of CRT in OSCC.
Copyright © 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29731125     DOI: 10.1016/j.crad.2018.03.015

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

1.  MRI-Based Radiomics and Urine Creatinine for the Differentiation of Renal Angiomyolipoma With Minimal Fat From Renal Cell Carcinoma: A Preliminary Study.

Authors:  Lian Jian; Yan Liu; Yu Xie; Shusuan Jiang; Mingji Ye; Huashan Lin
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 2.  The transformation of radiation oncology using real-time magnetic resonance guidance: A review.

Authors:  William A Hall; Eric S Paulson; Uulke A van der Heide; Clifton D Fuller; B W Raaymakers; Jan J W Lagendijk; X Allen Li; David A Jaffray; Laura A Dawson; Beth Erickson; Marcel Verheij; Kevin J Harrington; Arjun Sahgal; Percy Lee; Parag J Parikh; Michael F Bassetti; Clifford G Robinson; Bruce D Minsky; Ananya Choudhury; Robert J H A Tersteeg; Christopher J Schultz
Journal:  Eur J Cancer       Date:  2019-10-12       Impact factor: 9.162

3.  Predicting Early Response to Chemoradiotherapy for Uterine Cervical Cancer Using Intravoxel Incoherent Motion MR Imaging.

Authors:  Hiroki Kato; Kae Esaki; Takahiro Yamaguchi; Hidekazu Tanaka; Kimihiro Kajita; Tatsuro Furui; Ken-Ichirou Morishige; Satoshi Goshima; Masayuki Matsuo
Journal:  Magn Reson Med Sci       Date:  2019-02-19       Impact factor: 2.471

Review 4.  Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy.

Authors:  Petra J van Houdt; Yingli Yang; Uulke A van der Heide
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

5.  Review of MR-Guided Radiotherapy for Esophageal Cancer.

Authors:  Sangjune Laurence Lee; Michael Bassetti; Gert J Meijer; Stella Mook
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

Review 6.  The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer.

Authors:  Anna Pellat; Anthony Dohan; Philippe Soyer; Julie Veziant; Romain Coriat; Maximilien Barret
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.